Edwards Lifesciences Corp EW Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$102.14 up $1.32, 1.31% at close Nov 6
Last close · Previous close $100.82
- Market cap
- $58.87BAt the Nov 6 close
- P/E ratio
- 57.71On last 12 months’ EPS
- Diluted EPS
- $1.77Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$102.14up $1.32, 1.31%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$100.82Nov 5
- Volume5.11MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume4.64MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $74.66 to $104.17; now $102.14
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
EW beat the S&P 500 in 4 of 7 periods.
| Period | EW and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EW: up 18.1% S&P 500: down 5.6% | EW beat the S&P 500 by 23.7 percentage points Beat |
| 3M | EW: up 14.4% S&P 500: down 4.1% | EW beat the S&P 500 by 18.5 percentage points Beat |
| YTD | EW: up 19.8% S&P 500: up 8.7% | EW beat the S&P 500 by 11.1 percentage points Beat |
| 1Y | EW: up 23.9% S&P 500: up 10.9% | EW beat the S&P 500 by 13.0 percentage points Beat |
| Long term | ||
| 3Y | EW: up 52.2% S&P 500: up 75.0% +15.0% vs +20.5% a year | EW trailed the S&P 500 by 22.8 percentage points Trailed |
| 5Y | EW: down 13.9% S&P 500: up 67.8% −3.0% vs +10.9% a year | EW trailed the S&P 500 by 81.7 percentage points Trailed |
| 10Y | EW: up 241.9% S&P 500: up 313.1% +13.1% vs +15.2% a year | EW trailed the S&P 500 by 71.2 percentage points Trailed |
$10,000 invested in EW 10 years ago (Nov 4, 2016) would be worth about $34,187 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
EW beat the S&P 500 in 4 of 7 periods.
| Period | EW and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EW: up 18.1% S&P 500: down 5.6% | EW beat the S&P 500 by 23.7 percentage points Beat |
| 3M | EW: up 14.4% S&P 500: down 4.3% | EW beat the S&P 500 by 18.7 percentage points Beat |
| YTD | EW: up 19.8% S&P 500: up 7.8% | EW beat the S&P 500 by 12.0 percentage points Beat |
| 1Y | EW: up 23.9% S&P 500: up 9.7% | EW beat the S&P 500 by 14.2 percentage points Beat |
| Long term | ||
| 3Y | EW: up 52.2% S&P 500: up 68.8% +15.0% vs +19.1% a year | EW trailed the S&P 500 by 16.6 percentage points Trailed |
| 5Y | EW: down 13.9% S&P 500: up 56.9% −3.0% vs +9.4% a year | EW trailed the S&P 500 by 70.8 percentage points Trailed |
| 10Y | EW: up 241.9% S&P 500: up 252.6% +13.1% vs +13.4% a year | EW trailed the S&P 500 by 10.7 percentage points Trailed |
$10,000 invested in EW 10 years ago (Nov 4, 2016) would be worth about $34,187 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$130.68
Closing high on . Now 21.8% below that record.
Split-adjusted daily closes since Mar 27, 2000.
Stock splits
3
Latest: 3-for-1 on . One share bought before the first split is 12 shares today.
All 3 splits
- 3-for-1
- 2-for-1
- 2-for-1
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
57.7×The Nov 6 close ÷ diluted EPS over the last 12 months ($1.77)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
EW trades at 57.7× its earnings over the last 12 months, above its 5-year high of 57.7×. In plain terms, buyers are paying about $58 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 8.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 5.4×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 32.6×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 2.42%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $54.93BAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own EW DCF in Excel. Value Edwards Lifesciences with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $6.67Bup 13.4%
- Net income
- $1.02Bdown 25.3%
- Diluted EPS
- $1.77down 24.7%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $1.39B | $385.60M | $0.68 |
| Q1 FY25 (Mar 31, 2025) | $1.41B | $358.00M | $0.61 |
| Q2 FY25 (Jun 30, 2025) | $1.53B | $333.20M | $0.56 |
| Q3 FY25 (Sep 30, 2025) | $1.55B | $291.10M | $0.50 |
| Q4 FY25 (Dec 31, 2025) | $1.57B | $91.20M | $0.16 |
| Q1 FY26 (Mar 31, 2026) | $1.65B | $380.70M | $0.66 |
| Q2 FY26 (Jun 30, 2026) | $1.74B | $241.90M | $0.42 |
| Q3 FY26 (Sep 30, 2026) | $1.72B | $307.50M | $0.53 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $5.23B | $1.50B | $2.38 |
| FY22 (Dec 31, 2022) | $4.46B | $1.52B | $2.44 |
| FY23 (Dec 31, 2023) | $5.01B | $1.40B | $2.30 |
| FY24 (Dec 31, 2024) | $5.44B | $4.17B | $6.97 |
| FY25 (Dec 31, 2025) | $6.07B | $1.07B | $1.83 |
Margins
- Gross 78.0%
- Operating 17.6%
- Net 15.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $1.42BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$1.72BLast 12 months
- Capital spending$292.80MLast 12 months
- 21.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $563.10MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$563.10MLast 12 months
40% of free cash flow
Balance sheet
- $4.91BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$704.50MAs of Sep 30, 2026
- Net cash$4.20BAs of Sep 30, 2026
- 4.60As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.06As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 9.7%Last 12 months
Over the last 12 months, Edwards Lifesciences’s net income was 9.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 7.4%Last 12 months
Over the last 12 months, Edwards Lifesciences’s net income was 7.4% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Edwards Lifesciences Corp
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
EW news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
EW stock FAQ
What is EW stock’s price today?
Edwards Lifesciences (EW) traded at $102.14 at the close on , up $1.32 (1.31%) from the previous close of $100.82. Over the past 52 weeks it has traded between $74.66 and $104.17.
If you invested $1,000 in EW 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in EW on would be worth about $3,419 at the close on , a total return of +241.9%. The same $1,000 would be worth $861 if invested five years ago, $1,239 if invested one year ago, and $28,035 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market capitalization is about $58.9 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $102.14 (how market cap works). Edwards Lifesciences reported 576.40M shares outstanding at the end of its latest quarter ().
What is EW’s P/E ratio?
EW trades at 57.7 times its diluted earnings over the four quarters to ($1.77 per share), at the close. Over the past five years its P/E has ranged from 9.3 to 57.6, with a median of 36.0. (How the P/E ratio works.)
How much revenue does Edwards Lifesciences make?
Edwards Lifesciences reported $6.7 billion of revenue over the four quarters to , up 13.4% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.7 billion, up 10.5% from a year earlier.
Is Edwards Lifesciences profitable?
Yes. Edwards Lifesciences earned $1.0 billion of net income over the four quarters to , a net margin of 15.3%, and its operating margin was 17.6% (what margins tell you).
What are EW’s earnings per share?
EW’s diluted earnings per share were $1.77 over the four quarters to , compared with $2.35 in the twelve months before. The latest quarter (Q3 FY26) brought $0.53 per share, against $0.50 a year earlier (how EPS works).
Does EW pay a dividend?
Edwards Lifesciences hasn’t paid a dividend in the last twelve months.
What is EW’s 52-week high and low?
Over the past 52 weeks EW has traded as low as $74.66 and as high as $104.17. At $102.14 at the close on , it is 1.9% below that high and 36.8% above the low.
What is EW’s all-time high?
EW’s highest closing price was $130.68 on , adjusted for stock splits. At $102.14 at the close on , it is 21.8% below that record.
Has EW stock ever split?
Yes, three times: 2-for-1 on ; 2-for-1 on ; 3-for-1 on . One share bought before the first split would be 12 shares today.
How has EW stock performed?
Including dividends and measured to the close on , EW has returned +19.8% so far this year and +23.9% over the past year, and −13.9% over five years (−3.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Edwards Lifesciences in?
Edwards Lifesciences is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does EW trade on?
Edwards Lifesciences trades on the NYSE under the ticker symbol EW. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.